This study looks at how well a medicine called **Inaxaplin (IXP)** works for people with a specific kind of kidney disease called **proteinuric APOL1-mediated kidney disease (AMKD)**. In this type of kidney disease, proteins leak into urine. To join the study, people need a specific **APOL1 genotype** (G1/G1, G2/G2, or G1/G2), which is a kind of genetic pattern. Their **Estimated Glomerular Filtration Rate (eGFR)**, which shows how well kidneys filter waste, must be at least 25 mL/min/1.73m². People cannot join if they have another cause for kidney damage or if their blood pressure is not controlled.

• The study is **open-label**, meaning everyone knows they are taking Inaxaplin.
• No known compensation, but it checks for **safety and side effects**.
• Participants must have regular visits for monitoring.